AI Article Synopsis
- A novel gene called GPATCH2 was found to be overexpressed in most breast tumors analyzed, indicating its potential role in breast cancer.
- Treatment with siRNA to suppress GPATCH2 expression led to decreased growth in two breast cancer cell lines, MCF-7 and T47D, highlighting its importance in cancer cell proliferation.
- GPATCH2 interacts with the protein hPrp43, enhancing its activity and promoting cell growth, suggesting that targeting GPATCH2 or its interaction with hPrp43 could offer new treatment options for breast cancer.
Article Abstract
Through analysis of the detailed genome-wide gene expression profiles of 81 breast tumors, we identified a novel gene, G-patch domain containing 2 (GPATCH2), that was overexpressed in the great majority of breast cancer cases. Treatment of breast cancer cells MCF-7 and T47D with siRNA against GPATCH2 effectively suppressed its expression, and resulted in the growth suppression of cancer cells, suggesting its essential role in breast cancer cell growth. We found an interaction of GPATCH2 protein with hPrp43, an RNA-dependent ATPase. Their interaction could significantly enhance the ATPase activity of hPrp43 and induce a growth-promoting effect on mammalian cells. Because northern blot analyses of normal human organs implied GPATCH2 to be a novel cancer/testis antigen, targeting GPATCH2 or inhibition of the interaction between GPATCH2 and hPrp43 could be a promising novel therapeutic strategy of breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11158124 | PMC |
| http://dx.doi.org/10.1111/j.1349-7006.2009.01185.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!